Takeda Pharmaceutical Co. Ltd. Takes Position in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Takeda Pharmaceutical Co. Ltd. bought a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,475,121 shares of the company’s stock, valued at approximately $1,416,000. Xilio Therapeutics makes up about 5.3% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 3rd biggest holding. Takeda Pharmaceutical Co. Ltd. owned about 3.36% of Xilio Therapeutics at the end of the most recent quarter.

Separately, Raymond James Financial Inc. purchased a new stake in Xilio Therapeutics in the 4th quarter worth $48,000. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Stock Down 3.6 %

Shares of Xilio Therapeutics stock opened at $0.73 on Thursday. The company has a market capitalization of $37.95 million, a price-to-earnings ratio of -0.43 and a beta of -0.38. The stock’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $0.93. Xilio Therapeutics, Inc. has a 52 week low of $0.58 and a 52 week high of $1.93.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. The business had revenue of $1.72 million for the quarter, compared to the consensus estimate of $2.26 million. On average, equities analysts expect that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current year.

Xilio Therapeutics Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.